- Keywords > access - existing and new antimicrobial medicines and diagnostic tools
- Keywords > antibacterial resistance (ABR)
- Keywords > antibiotic resistance
- Keywords > antimicrobial resistance (AMR)
- Keywords > antimicrobial resistance surveillance
- Keywords > containment of antimicrobial resistance
- Keywords > drug resistance, microbial
- Keywords > new medicines
- Keywords > pharmaceutical research and development (R&D)
- Keywords > surveillance - antibiotic resistance and antibiotic use
- Keywords > confinement antimicrobien
(2019; 46 pages)
There is global commitment to address antimicrobial resistance through the Global Action Plan on Antimicrobial Resistance. High-impact communicable diseases, including tuberculosis (TB), human immunodeficiency virus (HIV), malaria and neglected tropical diseases (NTDs), should be integrated into and aligned with global antimicrobial resistance efforts.
Antimicrobial resistance puts achievement of Sustainable Development Goal 3 and other Sustainable Development Goals at risk, making effectively treating diseases more difficult and costly and leading to more illness and deaths.
Lessons learned from addressing antimicrobial resistance in TB and the other diseases during the past 20 years provide useful guidance for other antimicrobial resistance programmes in earlier stages of development, including:
- recognizing at an early stage the antimicrobial resistance challenge and advocating and mobilizing global development partners to address it;
- establishing a global antimicrobial resistance surveillance system;
- establishing direct drug resistance testing for individual patients, providing data for population-based surveillance;
- expanding and strengthening national and regional laboratory networks;
- strengthening country capacity for managing antimicrobial resistance;
- reaching out to stakeholders at all levels through a public–private mix, including engaging pharmacies and health-care providers to provide training on testing and treatment protocols; and
- establishing product development partnerships and research consortiums to facilitate the introduction of new pipeline drugs, review new drug formulations and develop improved diagnostic tests to detect antimicrobial resistance.